Top VHL Recombinant Protein For Human

Von Hippel-Lindau (VHLProtein Antagonist VH298 Improves Wound Therapeutic in Streptozotocin-Induced Hyperglycaemic Rats by Activating Hypoxia-Inducible Issue- (HIF-) 1 Signalling.

 

The aim of the current analysis is to analyze the results of the VHL protein antagonist, VH298, on purposeful actions of fibroblasts and vascular endothelial cells and the results on the wound therapeutic course of in a streptozotocin-induced hyperglycaemic rat mannequin.

Strategies

HIF-1α and hydroxy-HIF-1α protein ranges in VH298-treated rat fibroblasts (rFb) had been measured by immunoblotting, rFb proliferation was detected by the CCK-Eight assay, and mRNA ranges of associated genes had been measured by quantitative RT-PCR. In vitro wound therapeutic was simulated by the scratch take a look at; angiogenesis was measured by the human umbilical vein endothelial cell (hUVEC) tube formation assay. VH298 or PBS was regionally injected into wounds in rat fashions with streptozotocbd tissues had been harvested, and haematoxylin-eosin (HE) and Masson trichrome staining and immunohistochemical processes had been carried out.

Human Von Hippel Lindau Tumor Suppressor (vHL) ELISA Equipment

Outcomes

HIF-1α and hydroxy-HIF-1α ranges elevated in VH298-treated rFb, in a time- and dose-dependent method. Thirty micromolar VH298 may considerably enhance cell proliferation, angiogenesis, and gene expression of sort I collagen-αα

Conclusions

Taken collectively, VH298 activated the HIF-1 signalling pathway by stabilizing each HIF-1α and hydroxy-HIF-1α. VH298 enhanced rFb capabilities, promoted hUVEC angiogenesis, and accelerated wound therapeutic within the rat mannequin mimicking diabetes mellitus.

Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Equipment

 

 

VHL Antibody

1-CSB-PA876839
  • Ask for price
  • Ask for price
  • 100ug
  • 50ug
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC-p:1:50-300, ELISA:1:10000-20000

VHL Antibody

E19-6104 100μg/100μl
EUR 225
Description: Available in various conjugation types.

VHL Antibody

E18-6292-1 50μg/50μl
EUR 145
Description: Available in various conjugation types.

VHL Antibody

E18-6292-2 100μg/100μl
EUR 225
Description: Available in various conjugation types.

VHL Antibody

CSB-PA025852KA01HU- each
EUR 402
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200

VHL Antibody

CSB-PA025852KA01HU-100ul 100ul
EUR 466.8
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200

VHL Antibody

DF6104 200ul
EUR 420

VHL Antibody

DF6104-100ul 100ul
EUR 280

VHL Antibody

DF6104-200ul 200ul
EUR 350

VHL Antibody

E90377 100ul
EUR 255
Description: Available in various conjugation types.

VHL Antibody

E312859 200ul
EUR 275
Description: Available in various conjugation types.

VHL antibody

CAF50371-100ug 100ug
EUR 338

VHL antibody

70R-34605 100 ug
EUR 294
Description: Purified Rabbit polyclonal VHL antibody

VHL antibody

70R-9757 50 ug
EUR 467
Description: Affinity purified rabbit polyclonal VHL antibody

VHL Antibody

AF6292 200ul
EUR 420

VHL Antibody

AF6292-100ul 100ul
EUR 280

VHL Antibody

AF6292-200ul 200ul
EUR 350

VHL Antibody

1-CSB-PA060067
  • Ask for price
  • Ask for price
  • 100ug
  • 50ug
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/40000

VHL Antibody

1-CSB-PA071125
  • Ask for price
  • Ask for price
  • 100ul
  • 50ul
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:25-1:100

VHL Antibody

ABD6104 100ug
EUR 325

VHL Antibody

ABF6292 100ug
EUR 325

VHL Antibody

F49681-0.05ML 0.05 ml
EUR 140.25
Description: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein.

VHL Antibody

F49681-0.2ML 0.2 ml
EUR 322.15
Description: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein.

VHL Antibody

F49682-0.08ML 0.08 ml
EUR 140.25
Description: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein.

VHL Antibody

F49682-0.4ML 0.4 ml
EUR 330.65
Description: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein.

VHL Antibody

GWB-MV584H 50ug Ask for price

VHL Antibody

R35773-100UG 100 ug
EUR 339.15
Description: Additional name(s) for this target protein: Von Hippel-Lindau tumor suppressor, VHL1

VHL Antibody

MBS7124447-005mL 0.05mL
EUR 190

VHL Antibody

MBS7124447-01mL 0.1mL
EUR 270

VHL Antibody

MBS7124447-5x01mL 5x0.1mL
EUR 1205

VHL Antibody

MBS7124448-005mL 0.05mL
EUR 190

VHL Antibody

MBS7124448-01mL 0.1mL
EUR 270

VHL Antibody

MBS7124448-5x01mL 5x0.1mL
EUR 1205

VHL Antibody

MBS7120828-005mg 0.05mg
EUR 150

VHL Antibody

MBS7120828-01mg 0.1mg
EUR 190

VHL Antibody

MBS7120828-5x01mg 5x0.1mg
EUR 845

VHL Antibody

MBS7122921-005mg 0.05mg
EUR 150

VHL Antibody

MBS7122921-01mg 0.1mg
EUR 190

VHL Antibody

MBS7122921-5x01mg 5x0.1mg
EUR 845

VHL Antibody

MBS9412374-005mL 0.05mL
EUR 300

VHL Antibody

MBS9412374-01mL 0.1mL
EUR 390

VHL Antibody

MBS9412374-5x01mL 5x0.1mL
EUR 1610

VHL Antibody

MBS8512326-005mg 0.05mg
EUR 235

VHL Antibody

MBS8512326-01mg 0.1mg
EUR 305

VHL Antibody

MBS8512326-01mLAF405M 0.1mL(AF405M)
EUR 465

VHL Antibody

MBS8512326-01mLAF546 0.1mL(AF546)
EUR 465

VHL Antibody

MBS8512326-01mLAF750 0.1mL(AF750)
EUR 465

VHL Antibody

MBS8516021-01mg 0.1mg
EUR 305

VHL Antibody

MBS8516021-01mLAF405L 0.1mL(AF405L)
EUR 465

 

 

VHL Dependent Expression of REDD1 and PDK3 Proteins in Clear-cell Renal Cell Carcinoma.

 

 

  • Sporadic clear-cell renal cell carcinoma (ccRCC) is related with mutations within the VHL gene, upregulated mammalian goal of rapamycin (mTOR) exercise and glycolytic metabolism. Right here, we analyze the impact of VHL mutational standing on the expression stage of mTOR, eIF4E-BP1, AMPK, REDD1, and PDK3 proteins.

pGF-AP1-mCMV-EF1-Puro (293 secure cell line)

  • Complete proteins had been remoted from 21 tumorous samples with biallelic inactivation, 10 with monoallelic inactivation and 6 tumors with a wild-type VHL (wtVHL) gene obtained from sufferers who underwent complete nephrectomy. The expressions of goal proteins had been assessed utilizing Western blot.Expressions of mTOR, eIF4EBP1 and AMPOkay had been VHL impartial.

 

  • Tumors with monoallelic inactivation of VHL underexpressed REDD1 compared to wtVHL tumors (P = 0.042), tumors with biallelic VHL inactivation (P < 0.005) and management tissue (P = 0.004). Moreover, REDD1 expression was larger in tumors with VHL biallelic inactivation than in management tissue (P = 0.008). Solely in wt tumor samples PDK3 was overexpressed compared to tumors with biallelic inactivation of VHL gene (P = 0.012) and controls (P = 0.016). In wtVHL ccRCC, multivariate linear regression evaluation revealed that 97.4% of variability in PDK3 expression might be defined by variations in AMPK quantity.Expressions of mTOR, eIF4EBP1 and AMPK had been VHL impartial.

 

  • Now we have proven for the primary time VHL dependent expression of PDK3 and we offer extra proof that VHL mutational standing impacts REDD1 expression in sporadic ccRCC.

Gene Knock-Out HR Concentrating on Vector w/Single Choice Marker (Blasticidin) and Destructive Choice (TK) Towards Random Integration

  • Von Hippel-Lindau (VHL) illness is a uncommon hereditary most cancers syndrome that reduces life expectancy. We aimed to assemble a extra useful genotype-phenotype correlation primarily based on alterations in VHL protein (pVHL).

 

  • VHL sufferers (n = 339) had been recruited and grouped primarily based on mutation sorts: HIF-α binding web site missense (HM) mutations, non-HIF-α binding web site missense (nHM) mutations, and truncating (TR) mutations. Age-related dangers of VHL-associated tumors and affected person survival had been in contrast.

 

  • Missense mutations conferred an elevated danger of pheochromocytoma (HR = 1.854, p = 0.047) in contrast with truncating mutations. The danger of pheochromocytoma was decrease within the HM group than within the nHM group (HR = 0.298, p = 0.003) however was related between HM and TR teams (HR = 0.901, p = 0.810).

MUC16 CRISPR Knock Out Human OVCAR3-A1 Cell Line

T6230 1x10^6 cells / 1.0 ml Ask for price

Ccl2 CRISPR Knock Out CT26 Cell Line

T9611 1x10^6 cells / 1.0 ml Ask for price

CXCL8 CRISPR Knock Out L3.6pl Cell Line

T6220 1x10^6 cells / 1.0 ml Ask for price

CXCL1 CRISPR Knock Out L3.6pl Cell Line

T6221 1x10^6 cells / 1.0 ml Ask for price

SIRT CRISPR Knock Out Human HepG2 Cell Line - Clone T3-6

T6804 1x10^6 cells / 1.0 ml Ask for price

PRSS21 CRISPR Knock Out Human OVCAR8 Cell Line - Clone T2 C8

T6811 1x10^6 cells / 1.0 ml Ask for price

mAdrb2 CRISPR Knock Out B16 Cell Line (T1-10)

T9775 1x10^6 cells / 1.0 ml Ask for price

TREM2 CRISPR Knock Out Human THP-1 Cell Line - Clone T1-9

T6810 1x10^6 cells / 1.0 ml Ask for price

PTPN6 CRISPR Knock Out Human THP-1 Cell Line - Clone T3-1

T6813 1x10^6 cells / 1.0 ml Ask for price

MSLN CRISPR Knock Out Human OVCAR3-A1 Cell Line - Clone T2 C4

T6820 1x10^6 cells / 1.0 ml Ask for price

NR2F6 CRISPR Knock Out Human Jurkat E6.1 Cell Line - Clone T3-10

T6822 1x10^6 cells / 1.0 ml Ask for price

NUAK2 CRISPR Knock Out 293T Cell Line - Clone T3 #41

T6801 1x10^6 cells / 1.0 ml Ask for price

Aldh2 CRISPR Knock Out L929 Cell Line - Clone T3-20

T9692 1x10^6 cells / 1.0 ml Ask for price

hPIM1 CRISPR Knock Out SACC-83 Cell Line-T3-9

T9787 1x10^6 cells / 1.0 ml Ask for price

Dcx CRISPR Knock Out C6 Cell Line (Rat) - Clone sg4-1

T9624 1x10^6 cells / 1.0 ml
EUR 3950

GLT1 CRISPR Knock Out Rat AST Cell Line - Clone T2-1

T9678 1x10^6 cells / 1.0 ml Ask for price

PTPN11 CRISPR Knock Out NIH/3T3 Cell Line - Clone T4-9

T6803 1x10^6 cells / 1.0 ml Ask for price

METTL3 CRISPR Knock Out Caki-1 Cell Line - Clone T2-16

T9623 1x10^6 cells / 1.0 ml
EUR 3950

Nacc1 CRISPR Knock Out ID8 Cell Line (Mouse) - Clone T1-23

T9627 1x10^6 cells / 1.0 ml Ask for price

osbpl2 CRISPR Knock Out NIH/3T3 Cell Line - T1 Polyclonal Pool

T9682 1x10^6 cells / 1.0 ml Ask for price

CARMIL1 CRISPR Knock Out Immortalized Human Gingival Fibroblast - hTERT Cell Line - T1-2

T6825 1x10^6 cells / 1.0 ml Ask for price

Aifm1 CRISPR Knock Out Mouse L929 Cell Line - Clone T2-15-3

T9674 1x10^6 cells / 1.0 ml Ask for price

SEC61G CRISPR Knock Out HCC-LM3 Cell Line - Clone T2-17-5

T9746 1x10^6 cells / 1.0 ml Ask for price

Cell line gene knock-in and knock-out

S301 -
EUR 15000

293/GFP Cell Line

AKR-200 1 vial
EUR 460

293/Cas9 Cell Line

AKR-5110 1 vial
EUR 460

Human VHL knockdown HAP1 Cell Line

ABC-KD16757 1 vial Ask for price
Description: This cell line is engineered by our optimized transduction of the specific shRNA with lentivirus

Araf CRISPR Knocked out RAW264.7 Stable cell Cell Line (Mouse) T3-3

T9529 1x10^6 cells/1.0ml
EUR 3950

Araf CRISPR Knocked out RAW264.7 Stable cell Cell Line (Mouse) T1-19

T9511 1x10^6 cells / 1.0 ml
EUR 3950

Stable Mouse Myeloid-derived Suppressor-like LAL Knock Out (HD1B) Cell Line

T3187 1x10^6 cells / 1.0 ml
EUR 3950

BRCA1 CRISPR Stable Knockout Human Fibroblast Cell Line

T6245 1x10^6 cells / 1.0 ml
EUR 3950

293AD Cell Line

AD-100 1 vial
EUR 365

293AAV Cell Line

AAV-100 1 vial
EUR 405

293LTV Cell Line

LTV-100 1 vial
EUR 405

293RTV Cell Line

RV-100 1 vial
EUR 405

PTPRA CRISPR Knockout Immortalized Human Lung Fibroblast Cell Line

T6827 1x10^6 cells / 1.0 ml Ask for price

T47D/GFP Cell Line

AKR-208 1 vial
EUR 686.4
Description: T47D/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

A549/GFP Cell Line

AKR-209 1 vial
EUR 460

HeLa/GFP Cell Line

AKR-213 1 vial
EUR 460

HeLa/Cas9 Cell Line

AKR-5111 1 vial
EUR 460

Human CRISP1 knockout cell line

ABC-KH3569 1 vial Ask for price
Description: Human CRISP1 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology.

Human CRISP2 knockout cell line

ABC-KH3570 1 vial Ask for price
Description: Human CRISP2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology.

Human CRISP3 knockout cell line

ABC-KH3571 1 vial Ask for price
Description: Human CRISP3 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology.

NIH3T3/GFP Cell Line

AKR-214 1 vial
EUR 460

NIH3T3/Cas9 Cell Line

AKR-5104 1 vial
EUR 460

Acan CRISPR Knockout RCS Cell Line (Rat)

T3000 1x10^6 cells / 1.0 ml Ask for price

MCF-7/Luc Cell Line

AKR-234 1 vial
EUR 686.4
Description: MCF-7/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line.

Human CRISPLD1 knockout cell line

ABC-KH3572 1 vial Ask for price
Description: Human CRISPLD1 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology.

Human CRISPLD2 knockout cell line

ABC-KH3573 1 vial Ask for price
Description: Human CRISPLD2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology.

SKOV-3/Luc Cell Line

AKR-232 1 vial
EUR 686.4
Description: SKOV-3/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line.

OVCAR-5/RFP Cell Line

AKR-254 1 vial
EUR 686.4
Description: OVCAR-5/RFP Cell Line stably expresses RFP and otherwise exhibits the same characteristics of the parental cell line.

Human CRISP1 knockdown cell line

ABC-KD3569 1 vial Ask for price
Description: Human CRISP1 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest.

Human CRISP2 knockdown cell line

ABC-KD3570 1 vial Ask for price
Description: Human CRISP2 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest.

Human CRISP3 knockdown cell line

ABC-KD3571 1 vial Ask for price
Description: Human CRISP3 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest.

Human VHLL knockout cell line

ABC-KH16758 1 vial Ask for price
Description: Human VHLL knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology.

TARGATT? Knock-in Mouse Cell Line Generation Kit (Master Cell Line)

AST-7001 1 Kit Ask for price
Description: 6 month

Human CRISPLD1 knockdown cell line

ABC-KD3572 1 vial Ask for price
Description: Human CRISPLD1 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest.

Human CRISPLD2 knockdown cell line

ABC-KD3573 1 vial Ask for price
Description: Human CRISPLD2 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest.

GFAT1 CRISPR Stable Knockout H1299 Cell Line

T6199 1x10^6 cells / 1.0 ml
EUR 3950

EDC4 CRISPR Stable Knockout HEK293T Cell Line

T6241 1x10^6 cells / 1.0 ml
EUR 3950

Human VHLL knockdown cell line

ABC-KD16758 1 vial Ask for price
Description: Human VHLL knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest.

DJ-1 CRISPR Stable Knockout HeLa Cell Line

T6181 1x10^6 cells / 1.0 ml
EUR 3950

PDPN CRISPR Stable Knockout COS-7 Cell Line

T6039 1x10^6 cells / 1.0 ml
EUR 3950

PD-L1 CRISPR Stable Knockout CT26 Cell Line

T6237 1x10^6 cells / 1.0 ml
EUR 3950

PD-L1 CRISPR Stable Knockout MC38 Cell Line

T6149 1x10^6 cells / 1.0 ml
EUR 3950

LIMD1-/- CRISPR Stable Knockout HeLa Cell Line

T6357 1x10^6 cells / 1.0 ml
EUR 3950

SLC35A1 CRISPR Stable Knockout CHO-S Cell Line

T6040 1x10^6 cells / 1.0 ml
EUR 3950

CXCL1 & CXCL8 CRISPR Double Knockout L3.6pl Cell Line

T6047 1x10^6 cells / 1.0 ml Ask for price

TARGATT? Knock-in iPSC Generation (Master Cell Line)

AST-1100 1 vial of 1X10^6 cells Ask for price
Description: 6 month

Platinum-E Retroviral Packaging Cell Line, Ecotropic

RV-101 1 vial
EUR 770

Platinum-GP Retroviral Packaging Cell Line, Pantropic

RV-103 1 vial
EUR 770

Platinum-A Retroviral Packaging Cell Line, Amphotropic

RV-102 1 vial
EUR 770

Total Protein - Murine Embryonic Stem Cell Line D3

CBA-305 500 ?g
EUR 414
Description:
  • Isolated from mouse ES-D3 cell line
  • Presented as 500 µg at 1 mg/mL in NP-40 Solubilization Buffer

AXL CRISPR Stable Knockout HT1080 (1-IV) Cell Line

T6232 1x10^6 cells / 1.0 ml
EUR 3950

AXL CRISPR Stable Knockout HT1080 (3-II) Cell Line

T6233 1x10^6 cells / 1.0 ml
EUR 3950

PLN Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF)

iPS41 1 Vial
EUR 2268

LRP1 Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF)

iPS31 1 Vial
EUR 2268

AFF2 Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF)

iPS61 1 Vial
EUR 2268

ABCA7 Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF)

iPS21 1 Vial
EUR 2268

KCNK3 Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF)

iPS51 1 Vial
EUR 2268

LLGL1 Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF)

iPS71 1 Vial
EUR 2268

TARGATT? Knock-in CHO Generation Kit (Master Cell Line)

AST-1200 1 Kit Ask for price
Description: 12 month

TARGATT? Knock-in HEK293 Generation Kit (Master Cell Line)

AST-1300 1 Kit Ask for price
Description: 12 month

PTPN6 Stable Knocked Out THP-1 Cell Line

T6216 1x10^6 cells / 1.0 ml
EUR 3950

Human CRIM1 knockout cell line

ABC-KH3563 1 vial Ask for price
Description: Human CRIM1 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology.

Human CRIP1 knockout cell line

ABC-KH3564 1 vial Ask for price
Description: Human CRIP1 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology.

Human CRIP2 knockout cell line

ABC-KH3565 1 vial Ask for price
Description: Human CRIP2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology.

Human CRIP3 knockout cell line

ABC-KH3566 1 vial Ask for price
Description: Human CRIP3 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology.

Human CRIPT knockout cell line

ABC-KH3568 1 vial Ask for price
Description: Human CRIPT knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology.

Human CRIPAK knockout cell line

ABC-KH3567 1 vial Ask for price
Description: Human CRIPAK knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology.

  • Sufferers within the nHM group had the next danger of pheochromocytoma (HR = 3.447, p < 0.001) and decrease dangers of central nervous system hemangioblastoma (CHB) (HR = 0.700, p = 0.045), renal cell carcinoma (HR = 0.610, p = 0.024), and pancreatic tumor (HR = 0.382, p < 0.001) than these within the mixed HM and TR (HMTR) group.

 

  • Furthermore, nHM mutations had been independently related to better general survival (HR = 0.345, p = 0.005) and CHB-specific survival (HR = 0.129, p = 0.005) than HMTR mutations.

 

  • The modified genotype-phenotype correlation hyperlinks VHL gene mutation, substrate binding web site, and phenotypic range (penetrance and survival), and offers extra correct data for genetic counseling and pathogenesis research.

 

Leave A Comment